Defense World
15 Aug 2026, 07:33 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Zacks Research downgraded ADMA Biologics from a 'hold' to a 'strong sell' rating on August 4th. — A 'strong sell' rating from a major research firm typically triggers immediate negative sentiment and selling pressure.
-0.60Bank of America increased its position in ADMA Biologics by 107.5% in the first quarter. — Significant accumulation by a major institutional player suggests strong conviction in the company's long-term value.
+0.40Institutional ownership of ADMA Biologics currently stands at 75.68%. — High institutional ownership suggests a stable shareholder base and professional validation of the business model.
+0.20Continue reading
6 related stories
Search tags
ADMA Biologics reported quarterly earnings of $0.16 EPS, meeting consensus estimates. — Meeting expectations provides stability and prevents a negative surprise, though it doesn't act as a strong catalyst.
Quarterly revenue of $124.39 million slightly missed analyst estimates of $125.34 million. — A marginal revenue miss is generally a minor negative, though largely offset by the EPS hit.
-0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
53m ago
